AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04499716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obturator nerve block
Description: 20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.
Study NCT04499716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Description: 20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.
Study NCT04499716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: 20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.
Study NCT04499716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block
Description: 25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.
Study NCT04499716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral femoral cutaneous nerve block
Description: 5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.
Study NCT01548937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123 ADAM
Description: This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
Study NCT01069081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm C
Description: Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
Study NCT01069081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B
Description: Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
Study NCT01069081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A
Description: Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
Study NCT00825097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective tibial neurotomy
Description: Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
Study NCT00825097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin injection
Description: Botulinum toxin type A
Study NCT01581840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiochemotherapy
Description: Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
Study NCT01581840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 3 or 6 mg/kg (according to dose level)
Study NCT02304016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy
Description: Patients in this arm will be receiving pelvic floor physical therapy
Study NCT02062866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse-String
Description: The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound.
Study NCT02062866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second Intent
Description: The wound will not be sutured, and allowed to heal on its own.
Study NCT02821819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Random start ovarian stimulation
Description: Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
Study NCT02821819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotrophins
Description: Urinary FSH 150-225 IU/d
Study NCT02821819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
Study NCT02821819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
Study NCT03017157 — intervention group
Intervention type: OTHER
Intervention: Echo-cardiogram
Description: Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function
Study NCT03017157 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Blood test to determine thyroid function
Study NCT03354325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scheduled PCP follow-up
Description: Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
Study NCT03354325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: As needed PCP follow-up
Description: At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
Study NCT05296291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-translucent monolithic zirconia Bridge
Description: Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
Study NCT05296291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconium oxide ceramics Framework
Description: Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
Study NCT05296291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-ceramic Framework
Description: Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
Study NCT01398423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
Study NCT01398423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-144
Description: INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
Study NCT04005027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent graded exercise test
Description: Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
Study NCT04005027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent graded exercise test
Description: Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
Study NCT01445223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir ritonavir
Description: 400mg BD 100mg BD
Study NCT01445223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir ritonavir
Description: 300mg QD 100mg QD
Study NCT01445223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg QD
Study NCT03372837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
Study NCT02689934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoflorene colesterolo
Description: 1.8 g + 1.8 g once a day per os
Study NCT02689934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lactoflorene colesterolo
Description: 1.8 g + 1.8 g once a day per os
Study NCT04996290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG + LFCN block
Description: Regional anesthesia technique
Study NCT04996290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Local anesthetic used for peripheral nerve block.
Study NCT03584503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suction Above Cuff Endotracheal Tube
Description: Suction Above Cuff Endotracheal Tube (SACETT) has a dorsal port above the cuff designed to allow continuous or intermittent suctioning of secretions from the subglottic space
Study NCT01361373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L- DOPA
Description: Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
Study NCT01361373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 2 weeks
Study NCT00975988 — intervention group
Intervention type: DRUG
Intervention: TYKERB® tablets
Description: Patients administrated TYKERB® tablets according to the prescribing information
Study NCT00669903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328
Study NCT00669903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05622448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RPD with PEEK framework
Description: removable partial denture with CAD designed PEEK framework
Study NCT05622448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RPD with PEEK framework
Description: removable partial denture with CAD designed PEEK framework
Study NCT05622448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RPD with metallic framework
Description: removable partial denture with cobalt chromium framework
Study NCT05622448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RPD with metallic framework
Description: removable partial denture with cobalt chromium framework
Study NCT05822336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of Intramuscular Injections
Description: This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
Study NCT04069260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
Study NCT01624649 — intervention group
Intervention type: DRUG
Intervention: Methylphenidate hydrochloride
Description: Form = tablet, route = oral, administered as a flexible dosage
Study NCT01624649 — intervention group
Intervention type: DRUG
Intervention: Atomoxetine
Description: Form = tablet, route = oral;
Study NCT02232841 — intervention group
Intervention type: DEVICE
Intervention: Mechanical Ventilation
Description: Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
Study NCT02232841 — intervention group
Intervention type: DEVICE
Intervention: CT Scan
Description: Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
Study NCT01629680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxaverine
Description: Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
Study NCT01629680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: coated tablets identical in number and appearance as the study drug
Study NCT01121484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained-release
Description: 50-mg DVS SR tablets taken orally once daily.
Study NCT01121484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets taken orally once daily.
Study NCT00997737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DB, VI and FI
Description: Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
Study NCT04396080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial restoration in posterior teeth
Description: Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
Study NCT04803617 — intervention group
Intervention type: OTHER
Intervention: Assessment of pulmonary function and pectoralis muscle strength
Description: In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
Study NCT02712398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phasix™ ST
Description: Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
Study NCT00699140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV3I Grifols
Description: Immune Globulin Intravenous (Human)
Study NCT02704897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound Assessment Tool
Description: A set of questions relating to the symptoms of wound infection
Study NCT02523521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: physical activity program for a bronchopulmonary dysplasia children.
Study NCT04306939 — intervention group
Intervention type: OTHER
Intervention: venipuncture
Description: Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.
Study NCT04306939 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.
Study NCT00449488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: epoetin alfa 60.000 IU one i.v. bolus
Study NCT00452985 — intervention group
Intervention type: DRUG
Intervention: Docetaxel
Description: 60-75 mg/m²
Study NCT00452985 — intervention group
Intervention type: DRUG
Intervention: Carboplatin
Description: AUC 5
Study NCT04792593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Senl-h19 CAR-T
Description: Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
Study NCT00956592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMAC video laryngoscope
Description: Intubation utilizing the assistance of video enhancement
Study NCT00956592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study NCT04306939 — intervention group
Intervention type: OTHER
Intervention: Additional Sample Collections
Description: We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.
Study NCT02078505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: Carbohydrate poor diet
Study NCT02812472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training with functional electrical stimulation
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally.
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally.
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Administered orally.
Study NCT03214380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Administered orally.
Study NCT00256854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 1 mg
Description: Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.
Study NCT00256854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg
Description: Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.
Study NCT03761134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02812472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training without functional electrical stimulation
Study NCT00405405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: * Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy
Study NCT00405405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: * Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy
Study NCT00405405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy
Study NCT00405405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: * Two cycles during neoadjuvant therapy (dose escalation)~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy